搜尋結果
About lecanemab (LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s ...
About Brepacise. Brepacise is a dual-task exercise program that stimulates the body and brain by moving the arms and legs to music while also incorporating intellectual challenges. Eisai developed this product with the review of a physician as an easy and fun introductory exercise for those concerned about their brain health.
It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).5 Lecanemab is approved in the U.S.,6 Japan,7 and China.8 In the U.S., Japan and China, the indications are as follows: U.S.: For the treatment of Alzheimer’s disease (AD).
NouKNOW (non-medical device) is a tool developed by Eisai based on an algorithm created by Cogstate Ltd. (Headquarter: Australia), which uses a simple card test using a PC, tablet or smartphone device to perform tests evaluating psychomotor function, attention, learning and memory, and working memory.
About lecanemab (LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s ...
Chinese generic name: 仑卡奈单抗注射液 (lecanemab injection) Indication for use: Treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia Dosage and administration: The usual dose of lecanemab (recombinant) is 10mg/kg infused intravenously over approximately 1 hour, once every 2 weeks.
Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings on its Alzheimer’s disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), at the Alzhei...
